Difluprednate
 | |
| Systematic (IUPAC) name | |
|---|---|
|
[(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a609025 |
| Licence data | US FDA:link |
| Legal status |
|
| Routes of administration | topical dermatologic |
| Identifiers | |
| CAS Number |
23674-86-4  |
| ATC code | D07AC19 |
| PubChem | CID 32037 |
| DrugBank |
DB06781  |
| ChemSpider |
391990 |
| UNII |
S8A06QG2QE |
| KEGG |
D01266 |
| ChEMBL |
CHEMBL1201749 |
| Chemical data | |
| Formula | C27H34F2O7 |
| Molar mass | 508.551 |
| (what is this?) (verify) | |
Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.
Approval
On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain.[1] It is marketed by Alcon under the tradename Durezol.
Clinical trials
Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating difluprednate for the treatment of anterior uveitis.[2]
References
- ↑ "Sirion Therapeutics Announces FDA Approval of Durezol for Treatment of Postoperative Ocular Inflammation and Pain" (Press release). Sirion Therapeutics, Inc. 2008-06-24. Retrieved 2008-06-30.
- ↑ ClinicalTrials.gov
| ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, March 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.